Primmune Therapeutics Funding: $23M Raised, Series B (2026)
Primmune Therapeutics is a Biotech company based in San Diego. It has raised $23M in total funding. Latest round: Series B.
Primmune Therapeutics funding overview
Primmune Therapeutics is a Biotech company based in San Diego. Primmune Therapeutics has raised $23M in total disclosed funding. That places its disclosed total in the $1M–$25M range. Its most recent disclosed round is a Series B announced in January 2026. The round record for Primmune Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include Bioqube Ventures, Oberland Capital, Samsara Biocapital. 3 distinct backers are named across the disclosed rounds.
Frequently asked about Primmune Therapeutics funding
How much has Primmune Therapeutics raised?
Primmune Therapeutics has raised $23M in total disclosed funding across the rounds on record.
Who has invested in Primmune Therapeutics?
Bioqube Ventures, Oberland Capital, Samsara Biocapital are named among the investors backing Primmune Therapeutics.
What was the latest Primmune Therapeutics funding round?
The most recent disclosed round is a Series B, announced in January 2026.
Where is Primmune Therapeutics based?
Primmune Therapeutics is based in San Diego.
What sector does Primmune Therapeutics operate in?
Primmune Therapeutics is tracked under Biotech from San Diego, with $23M in disclosed funding.
When did Primmune Therapeutics last raise?
The last disclosed Primmune Therapeutics round closed in January 2026 at Series B.
Round data for Primmune Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies in San Diego and backer lists below.
